Pfizer Corporation

Sanford Burnham Prebys Medical Discovery Institute

Biogen Ma Inc.

Tigran Aivazian

Brian Miller

Carl F Ware

John Sedy

Natasha K Crellin

Justin Andrew Caravella

Scott Glaser

Susan Foley

Xiaoping Hronowski

The present invention is based on the seminal discovery that BTLA agonist fusion proteins modulate an immune response. Specifically, the present invention provides fusion proteins that bind BTLA enhancing BTLA signaling. The present invention further provides methods of treating cancer and immune and inflammatory diseases and disorders with a BTLA agonist fusion protein as described herein.

BTLA fusion protein agonists and uses thereof

The invention is based, at least in part, on the finding that linker peptides which lack the amino acid sequence GSG reduce or eliminate the addition of posttranslational modifications to the polypeptides which comprise them. More specifically, the novel linker peptides disclosed herein reduce the ability of enzymes to link carbohydrate adducts to polypeptides comprising these linker peptides, e.g., reduce the ability of xylosyltransferase to link xylose to polypeptides. These novel linker peptides, molecules comprising same, and methods of their use are described.

Linker peptides and polypeptides comprising same

Growing community of inventors

San Diego, CA, United States of America

Tigran Aivazian